Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Table of Contents | Next Article »
Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:1535-1537
doi: 10.1161/01.ATV.0000141044.03875.7f
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Parmacek, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parmacek, M. S.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:1535.)
© 2004 American Heart Association, Inc.

Editorials

Myocardin—Not Quite MyoD

Michael S. Parmacek

From the Department of Medicine (Molecular Cardiology), University of Pennsylvania, Philadelphia, Pa.

Correspondence to Michael S. Parmacek, MD, Division of Cardiovascular Medicine, Department of Medicine, University of Pennsylvania School of Medicine, 9123 Founders Pavilion, 3400 Spruce St., Philadelphia, PA 19104, E-mail Michael.parmacek{at}uphs.upenn.edu

Smooth muscle cells (SMCs) have evolved to subserve a variety of diverse functions in higher vertebrates, including modulation of arterial tone, regulation of airway resistance, and control of gastrointestinal motility. The diverse functional capacities of SMCs are ultimately determined by the expression of genes encoding SMC-restricted contractile and cytoskeletal proteins, intracellular enzymes, cell surface ligands, and receptors. Several features distinguish the SMC lineage from the skeletal (fast and slow) and cardiac muscle cell lineages. In contrast to skeletal and cardiac muscle cells, SMCs fail to undergo terminal differentiation and permanently exit the cell cycle. In addition, SMCs retain the capacity to reversibly modulate their phenotype during postnatal development in response to a variety of extracellular stimuli including vessel wall injury. As such, the molecular programs underlying SMC differentiation must differ fundamentally from those programs governing skeletal and cardiac myocyte differentiation.

See page 1596

Relatively little is currently understood about the molecular mechanisms that regulate SMC lineage specification, differentiation, and modulation of SMC phenotype. This is because, in part, of the complex embryological origins of the SMC lineage, which are derived both from mesodermally-derived lateral mesenchyme as well as ectodermally-derived neural crest. In addition, in contrast to skeletal and cardiac lineages, relatively few definitive markers of the SMC lineage have been identified, and expression of these markers may be undetectable when SMCs modulate their phenotype from contractile to synthetic (for review see Owens1). SM-myosin heavy chain (SMyHC) is generally considered the "definitive" SMC marker because it is expressed exclusively in SMCs and is not expressed in embryonic skeletal or cardiac muscle.2 Other SMC markers including SM-{alpha}-actin, calponin-h1, and SM22{alpha} are expressed predominantly in SMCs during postnatal development, but they are also transiently expressed in embryonic cardiac and/or skeletal myocytes (and/or other cell lineages).1 Each of these SMC markers is expressed at high levels in freshly isolated rat aortic SMCs, but their relative levels of expression decrease dramatically with serial passage in cell culture.3,4 For this reason these SMC markers are generally considered markers of a "contractile" SMC phenotype, though this is somewhat misleading as these genes are also expressed at high levels in proliferating SMCs during embryonic angiogenesis and in the fibrous caps of atherosclerotic plaques.4–6

The expression of genes encoding contractile SMC markers, including SMyHC, SM-{alpha}-actin, SM22{alpha}, and calponin-h1, is critically dependent on a serum response factor (SRF)-dependent transcriptional program (for review see Parmacek7 and Miano8). SRF is a 508-aa protein that is a member of the ancient MADS box family of transcription factors.9 The conserved MADS box domain of SRF mediates both DNA-binding activity and heterodimerization with other transcription factors. SRF was originally cloned and characterized because in serum-stimulated cells it binds to, and transactivated, the growth responsive c-fos promoter.9 Subsequently, it was shown that SRF plays an important role in activating transcription of some skeletal- and cardiac-specific genes including {alpha}-cardiac actin and {alpha}-skeletal actin.10,11 SRF binds the consensus nucleotide sequence (CC(A/T)6GG), which has been variably designated as an SRE or CArG box, as a homodimer or heterodimeric protein complex.12 Transcriptional activity of SRF is regulated by multiple mechanisms including: (1) direct binding of other (lineage-restricted) transcription factors,13–17 (2) posttranslational modifications of SRF,18 (3) posttranslational modifications of ternary complex factors that bind to SRF,19,20 and (4) alternative-splicing.21,22 Functionally important CArG boxes have been identified in the promoters and/or transcriptional enhancers controlling expression of the SM-MyHC, SM-{alpha}-actin, SM22{alpha}, calponin-h1, and telokin genes.7,8 Mutations that abolish binding of SRF to these transcriptional regulatory elements abolished transcriptional activity of these elements in transgenic mice. Moreover, a multimerized copy of the SM22{alpha} CArG box restricts transgene expression to arterial SMCs in transgenic mice.23

Because of its ability to transduce extracellular, cytoskeletal, and intracellular signals and its capacity to activate genes encoding SMC contractile markers, it was postulated that SRF serves as a "nuclear-sensor" integrating multiple extracellular and intracellular signals and regulating SMC phenotype.7 However, until the discovery of myocardin it remained unclear how SRF, which is expressed ubiquitously, could regulate a subset of SMC-restricted genes and thereby SMC differentiation and phenotype. In skeletal muscle cells, the related MADS box transcription factor MEF2 binds to DNA and heterodimerizes with the skeletal muscle-specific transcription factor MyoD to synergistically activate skeletal muscle-specific transcriptional regulatory elements.24 Similarly in the heart, SRF heterodimerizes with the cardiac muscle-restricted transcription factors Nkx-2.5 and GATA4 and activates a set of cardiac-specific genes.16,17 SRF serves to dock these lineage restricted transcription factors to specific CArG motifs, and together they activate transcription. Based on this paradigm we and others hypothesized that a SMC lineage-restricted transcription factor may exist and act as a SRF cofactor in SMCs.

Using an in silico cloning strategy, Olson and colleagues cloned myocardin and demonstrated that myocardin is a remarkably potent transcriptional activator of SRF-dependent genes including SM22{alpha}.15 In addition, they reported that myocardin gene expression is restricted to the heart and SMC-containing tissues. Shortly thereafter our group and others reported that forced expression of myocardin activates transcription of multiple genes encoding SMC contractile markers including SMyHC, SM-{alpha}-actin, SM22{alpha}, and calponin-h1.25–28 In addition, we reported that knockdown of myocardin gene expression in SMCs, by either siRNA or over-expression of a dominant-negative myocardin mutant, suppresses transcription of genes encoding SMC contractile markers.25 Remarkably, our group and others found that forced expression of myocardin in undifferentiated embryonic stem (ES) cells and several other cell types activates expression of endogenous SMC markers including SMyHC, SM-{alpha}-actin, calponin-h1, and SM22{alpha}.25,27,28 Consistent with these findings, Olson and colleagues reported that myocardin-deficient mice die at embryonic day (E)10.5 and show no evidence of vascular SMC differentiation.29 These compelling data led some to conclude that myocardin is a "master regulator" of the SMC gene expression.28

The concept of a master-regulatory gene originated when Lassar and Weintraub cloned and characterized the skeletal muscle-specific basic helix-loop-helix (bHLH) transcription factor MyoD.30 Remarkably, Lassar and Weintraub demonstrated that forced expression of MyoD causes C3H10T1/2 fibroblasts to adopt a skeletal muscle cell fate. Subsequently, it was shown that MyoD is a member of a larger family of skeletal muscle-specific bHLH transcription factors, each member of which possesses the capacity to drive cells to a skeletal muscle cell fate (for review see Olson31). It is noteworthy that MyoD family members are expressed exclusively in skeletal muscle cells and the myotomal component of the somites whereas myocardin is expressed in both cardiac myocytes and SMCs. Moreover, at the level of sensitivity provided by in situ hybridization, myocardin is not detectable in all vascular SMCs during embryonic development.25 It is also noteworthy that forced expression of MyoD leads to expression of the full repertoire of skeletal muscle genes, and these cells exhibit the electrophysiological and mechanical properties of differentiated skeletal muscle.

The data presented by Yoshida and colleagues in this issue of Arteriosclerosis, Thrombosis, and Vascular Biology suggests that the conclusion that myocardin is a master regulator of the SMC gene expression requires qualification or may be premature.32 As shown in the Figure, Yoshida observed that forced expression of myocardin activates a subset of SRF-dependent SMC contractile genes.25,27,28 However, expression of other genes expressed in SMCs, including smoothelin-B, aortic carboxypeptidase-like protein (ACLP), and focal adhesion kinase-related nonkinase (FRNK), which reportedly are not CArG box-dependent, was not observed.33 This observation is consistent with a recent report showing that expression of the histone rich calcium-binding protein (HRC) in smooth, cardiac, and skeletal muscle is controlled by a MEF2-dependent myocardin-independent promoter.34 Moreover, forced expression of myocardin also induced expression of cardiac- and skeletal muscle-specific genes including atrial natriuretic factor, cardiac {alpha}-actin, and skeletal {alpha}-actin. Expression of this subset of cardiac and skeletal muscle-specific genes is also dependent on SRF. Thus it appears that myocardin activates SRF-dependent SMC contractile genes (as well as SRF-dependent cardiac- and skeletal muscle-dependent genes), but alone is not sufficient to activate the full repertoire of genes expressed in SMCs. Together, the existing experimental evidence suggests a model wherein myocardin is required for SMC differentiation and promotes the contractile SMC phenotype, but alone is not sufficient to convert undifferentiated cells to the SMC lineage.



View larger version (16K):
[in this window]
[in a new window]
  		Schematic model of myocardin-dependent and myocardin-independent SMC gene expression. Forced expression of myocardin (and MRTF-A) has the capacity to activate a subset of SMC genes usually associated with a contractile SMC phenotype including SM-MyHC, SM-{alpha}-actin, SM22{alpha}, calponin-h1, telokin, and desmin. Myocardin (and MRTF-A) activate transcription by heterodimerizing to the MADS box domain of SRF which in turn binds directly to specific CArG motifs located in transcriptional regulatory regions controlling expression of these SMC genes. In contrast, a subset of genes expressed in SMCs is controlled in a myocardin (and SRF)-independent fashion. These genes include FRNK, ACLP, Smoothelin-B, and HRC. Candidate transcription factors regulating expression of these genes include MEF2, GATA6, Ets-1, and members of the kruppel-like family of transcription factors (KLFs).

These data suggest strongly that SMC differentiation in vivo requires one or more signals, in addition to myocardin, that was/were not provided under the experimental conditions used. In the vasculature strong candidates include endothelial cell-derived growth factor(s). Alternatively, the precise concentration of myocardin or the myocardin to SRF ratio may be a critical determinant of SMC differentiation in vivo.15 Finally, the role of the two recently described myocardin-related transcription factors must also be considered.35,36 Nevertheless, the discovery of myocardin, and two myocardin-related transcription factors, 35,36 has opened up exciting new avenues of investigation that promise to provide important insights into the molecular program underlying SMC differentiation and the modulation of SMC phenotype.

Acknowledgments

This manuscript was supported in part by National Institutes of Health grants R01-56915 and PO-1 HL075380 (to M.S.P.).

References

  1. Owens GK. Molecular control of vascular smooth muscle cell differentiation. Acta Physiol Scand. 1998; 164: 623–635.[Medline] [Order article via Infotrieve]
  2. Miano JM, Cserjesi P, Ligon KL, Periasamy M, Olson EN. Smooth muscle myosin heavy chain exclusively marks the smooth muscle lineage during mouse embryogenesis. Circ Res. 1994; 75: 803–812.[Abstract/Free Full Text]
  3. Kumar MS, Owens GK. Combinatorial control of smooth muscle-specific gene expression. Arterioscler Thromb Vasc Biol. 2003; 23: 737–747.[Abstract/Free Full Text]
  4. Campbell GR, Campbell JH, Manderson JA, Horrigan S, Rennick RE. Arterial smooth muscle: a multifunctional mesenchymal cell. Arch Pathol Lab Med. 1988; 112: 977–986.[Medline] [Order article via Infotrieve]
  5. Shanahan CM, Weissberg PL, Metcalfe JC. Isolation of gene markers of differentiated and proliferating vascular smooth muscle cells. Circ Res. 1993; 73: 193–204.[Abstract]
  6. Shanahan CM, Weissberg PL. Smooth muscle cell phenotypes in atherosclerotic lesions. Curr Opin Lipidol. 1999; 10: 507–513.[CrossRef][Medline] [Order article via Infotrieve]
  7. Parmacek MS. Transcriptional programs regulating vascular smooth muscle cell development and differentiation. Curr Top Dev Biol. 2001; 51: 69–89.[Medline] [Order article via Infotrieve]
  8. Miano JM. Serum response factor: toggling between disparate programs of gene expression. J Mol Cell Cardiol. 2003; 35: 577–593.[CrossRef][Medline] [Order article via Infotrieve]
  9. Treisman R. Identification and purification of a polypeptide that binds to the c-fos serum response element. EMBO J. 1987; 6: 2711–2717.[Medline] [Order article via Infotrieve]
  10. Bergsma DJ, Grichnik JM, Gossett LM, Schwartz RJ. Delimitation and characterization of cis-acting DNA sequences required for the regulated expression and transcriptional control of the chicken skeletal alpha-actin gene. Mol Cell Biol. 1986; 6: 2462–2475.[Abstract/Free Full Text]
  11. Minty A, Kedes L. Upstream regions of the human cardiac actin gene that modulate its transcription in muscle cells: presence of an evolutionarily conserved repeated motif. Mol Cell Biol. 1986; 6: 2125–2136.[Abstract/Free Full Text]
  12. Mohun TJ, Chambers AE, Towers N, Taylor MV. Expression of genes encoding the transcription factor SRF during early development of Xenopus laevis: identification of a CArG box-binding activity as SRF. EMBO J. 1991; 10: 933–940.[Medline] [Order article via Infotrieve]
  13. Price MA, Rogers AE, Treisman R. Comparative analysis of the ternary complex factors Elk-1, SAP-1a and SAP-2 (ERP/NET). EMBO J. 1995; 14: 2589–2601.[Medline] [Order article via Infotrieve]
  14. Treisman R. Ternary complex factors: growth factor regulated transcriptional activators. Curr Opin Genet Dev. 1994; 4: 96–101.[CrossRef][Medline] [Order article via Infotrieve]
  15. Wang D, Chang PS, Wang Z, Sutherland L, Richardson JA, Small E, Krieg PA, Olson EN. Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor. Cell. 2001; 105: 851–862.[CrossRef][Medline] [Order article via Infotrieve]
  16. Chen CY, Schwartz RJ. Recruitment of the tinman homolog Nkx-2.5 by serum response factor activates cardiac alpha-actin gene transcription. Mol Cell Biol. 1996; 16: 6372–6384.[Abstract]
  17. Sepulveda JL, Belaguli N, Nigam V, Chen CY, Nemer M, Schwartz RJ. GATA-4 and Nkx-2.5 coactivate Nkx-2 DNA binding targets: role for regulating early cardiac gene expression. Mol Cell Biol. 1998; 18: 3405–3415.[Abstract/Free Full Text]
  18. Marais RM, Hsuan JJ, McGuigan C, Wynne J, Treisman R. Casein kinase II phosphorylation increases the rate of serum response factor-binding site exchange. EMBO J. 1992; 11: 97–105.[Medline] [Order article via Infotrieve]
  19. Hill CS, Treisman R. Differential activation of c-fos promoter elements by serum, lysophosphatidic acid, G proteins and polypeptide growth factors. EMBO J. 1995; 14: 5037–5047.[Medline] [Order article via Infotrieve]
  20. Price MA, Cruzalegui FH, Treisman R. The p38 and ERK MAP kinase pathways cooperate to activate Ternary Complex Factors and c-fos transcription in response to UV light. EMBO J. 1996; 15: 6552–6563.[Medline] [Order article via Infotrieve]
  21. Belaguli NS, Zhou W, Trinh T-HT, Majesky MW, Schwartz RJ. Dominant negative murine serum response factor: Alternative splicing within the activation domain inhibits transactivation of serum response factor binding targets. Mol Cell Biol. 1999; 19: 4582–4591.[Abstract/Free Full Text]
  22. Kemp PR, Metcalfe JC. Four isoforms of serum response factor that increase or inhibit smooth muscle-specific promoter activity. Biochem J. 2000; 345: 445–451.
  23. Strobeck M, Kim S, Zhang JC, Clendenin C, Du KL, Parmacek MS. Binding of serum response factor to CArG box sequences is necessary but not sufficient to restrict gene expression to arterial smooth muscle cells. J Biol Chem. 2001; 276: 16418–16424.[Abstract/Free Full Text]
  24. Molkentin JD, Black BL, Martin JF, Olson EN. Cooperative activation of muscle gene expression by MEF2 and myogenic bHLH proteins. Cell. 1995; 83: 1125–1136.[CrossRef][Medline] [Order article via Infotrieve]
  25. Du KL, Ip HS, Li J, Chen M, Dandre F, Yu W, Lu MM, Owens GK, Parmacek MS. Myocardin is a critical serum response factor cofactor in the transcriptional program regulating smooth muscle cell differentiation. Mol Cell Biol. 2003; 23: 2425–2437.[Abstract/Free Full Text]
  26. Chen J, Kitchen CM, Streb JW, Miano JM. Myocardin: a component of a molecular switch for smooth muscle differentiation. J Mol Cell Cardiol. 2002; 34: 1345–1356.[CrossRef][Medline] [Order article via Infotrieve]
  27. Yoshida T, Sinha S, Dandre F, Wamhoff BR, Hoofnagle MH, Kremer BE, Wang DZ, Olson EN, Owens GK. Myocardin is a key regulator of CArG-dependent transcription of multiple smooth muscle marker genes. Circ Res. 2003; 92: 856–864.[Abstract/Free Full Text]
  28. Wang Z, Wang DZ, Pipes GC, Olson EN. Myocardin is a master regulator of smooth muscle gene expression. Proc Natl Acad Sci U S A. 2003; 100: 7129–7134.[Abstract/Free Full Text]
  29. Li S, Wang DZ, Wang Z, Richardson JA, Olson EN. The serum response factor coactivator myocardin is required for vascular smooth muscle development. Proc Natl Acad Sci U S A. 2003.
  30. Lassar AB, Buskin JN, Lockshon D, Davis RL, Apone S, Hauschka SD, Weintraub H. MyoD is a sequence-specific DNA binding protein requiring a region of myc homology to bind to the muscle creatine kinase enhancer. Cell. 1989; 58: 823–831.[CrossRef][Medline] [Order article via Infotrieve]
  31. Olson EN. Regulation of muscle transcription by the MyoD family. The heart of the matter. Circ Res. 1993; 72: 1–6.[Abstract/Free Full Text]
  32. Yoshida T, Kawai-Kowase K, Owens GK. Forced expression of myocardin is not sufficient for induction of smooth muscle differentiation in multipotential embryonic cells. Arterioscler Thromb Vasc Biol. 2004; 24: 1596–1601.[Abstract/Free Full Text]
  33. Rensen SS, Thijssen VL, De Vries CJ, Doevendans PA, Detera-Wadleigh SD, Van Eys GJ. Expression of the smoothelin gene is mediated by alternative promoters. Cardiovasc Res. 2002; 55: 850–863.[Abstract/Free Full Text]
  34. Anderson JP, Dodou E, Heidt AB, De Val SJ, Jaehnig EJ, Greene SB, Olson EN, Black BL. HRC is a direct transcriptional target of MEF2 during cardiac, skeletal, and arterial smooth muscle development in vivo. Mol Cell Biol. 2004; 24: 3757–3768.[Abstract/Free Full Text]
  35. Wang DZ, Li S, Hockemeyer D, Sutherland L, Wang Z, Schratt G, Richardson JA, Nordheim A, Olson EN. Potentiation of serum response factor activity by a family of myocardin-related transcription factors. Proc Natl Acad Sci U S A. 2002; 99: 14855–14860.[Abstract/Free Full Text]
  36. Du KL, Chen M, Li J, Lepore JJ, Mericko P, Parmacek MS. Megakaryoblastic leukemia factor-1 transduces cytoskeletal signals and induces smooth muscle cell differentiation from undifferentiated embryonic stem cells. J Biol Chem. 2004; 279: 17578–17586.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Circ. Res.Home page
M. S. Parmacek
Myocardin-Related Transcription Factors: Critical Coactivators Regulating Cardiovascular Development and Adaptation
Circ. Res., March 16, 2007; 100(5): 633 - 644.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Parmacek, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parmacek, M. S.

ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.